Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

http://www.businessweek.com/ap/2013-03-20/cerecor-acquires-merck-experimental-drugs

AP News

Cerecor acquires Merck experimental drugs


NEW YORK (AP) — Cerecor, a development-stage biotechnology company, said Wednesday it agreed to acquire potential treatments for Parkinson's disease and other central nervous system disorders from Merck & Co.

Cerecor Inc. of Baltimore said it is gaining the worldwide rights to develop and market drugs called COMT inhibitors. COMT is an enzyme that breaks down dopamine, and drugs that block COMT have been used to treat Parkinson's disease. Cerecor said it's possible that COMT inhibitors could also be used to treat schizophrenia and addiction.

Cerecor said it will review more than 2,000 potential drugs and select some for clinical development. Merck can get milestone payments and royalties from sales of any drugs that are approved. The companies did not disclose specific terms of the deal.

Merck, based in Whitehouse Station, N.J., is one of the world's biggest drug companies. Shares of the company rose 45 cents to $44.15 in morning trading.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus